Fundz

Byondis Appoints Louis Denis, M.D. as Chief Medical Officer

Nov 19, 2024

Position

Chief Medical Officer

Company

Byondis B.V

Louis Denis
louis.denis@byondis.com
NijmegenBiotechnologyHealth CareTherapeuticsBiopharma

Description

Byondis B.V. announces the appointment of Louis Denis, M.D. as Chief Medical Officer

Quick answer

Byondis Appoints Louis Denis, M.D. as Chief Medical Officer (November 19, 2024). Byondis B.V is based in Nijmegen, Gelderland, Netherlands.

Who is the new Chief Medical Officer at Byondis B.V?
Byondis B.V named Louis Denis Chief Medical Officer, announced November 19, 2024.
What did Byondis B.V announce on November 19, 2024?
Byondis B.V. announces the appointment of Louis Denis, M.D. as Chief Medical Officer
What does Byondis B.V do?
Byondis is an independent clinical stage biopharmaceutical company creating innovative targeted medicines for cancer.
Where is Byondis B.V based?
Byondis B.V is based in Nijmegen, Gelderland, Netherlands.
Which similar companies made leadership changes around the same time?
NRx Pharmaceuticals (November 18, 2024), Arecor Therapeutics PLC (November 18, 2024), BerGenBio ASA (November 20, 2024) and Altimmune (November 11, 2024) also announced leadership changes within 45 days of Byondis B.V.

Source: Fundz verified event record.

Other recent leadership changes in Therapeutics and Biopharma

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Byondis B.V, and when

A new leader at Byondis B.V brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Byondis B.V raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Byondis B.V, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Byondis B.V. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Byondis B.V

Location

Nijmegen, Gelderland, Netherlands

About

Byondis is an independent clinical stage biopharmaceutical company creating innovative targeted medicines for cancer. The company is developing new biological entities (NBEs) focusing on antibody-drug conjugates and antibody-based therapeutics.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Byondis B.V changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Louis
Likely contact at this company
••••••••@••••••••

See Louis's verified email →

Christoph
Likely contact at this company
••••••••@••••••••

See Christoph's verified email →

Richard
Senior decision-maker at this company
••••••••@••••••••

See Richard's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Byondis B.V's next move

Learn about Strategic plan

Byondis B.V changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.